Various diseases have troubled the minds of the caring doctors and researchers in finding their cure which has not yet been found. This has called for collaborations and partnership with various organizations and donors to finance research to help come up with the cure for such diseases. Some of the genetic disorders that are keeping many medical practitioners busy and awake are Myotonic Dystrophy type 1 commonly called DM1 which is responsible for muscular dystrophy, especially in adults. This has made Scott Rocklage and Expansion Therapeutics bring along research teams on board.
Scott Rocklage studied B.Sc. Degree in Chemistry at the University of California then proceeded to MIT for his Ph.D. in Chemistry and while here did a research in Dr. Schrock Laboratory which made Schrock receive the Nobel Peace Prize in the Year 2005. In 2003, Scott became a Venture Partner with 5AM Ventures and after a year he became the Managing Partner a position he holds till now. He served as a Board Chairman at Novira, Relypsa, Pulmatrix, WaveRX among others.
The successful legend has over three decades in healthcare management where he has written over 100 publications and over 30 United States patents which he has either invented or co-invented. Basically, he is a medical inventor who has presented several medications for some clinical tests and trials. He is tasked with a responsibility of receiving Cubicin, Teslascan and Omniscan medications that they have been received. Scott Rocklage has served as a CEO and Chairman in Cubist Pharmaceuticals and in Nycomed Salutar as the CEO and President. Besides he has worked with Catalytica.
5AM Venture is among those that are supporting Expansion Therapeutics financially. The DM1 disease is mild and it only displays its symptoms when RNAs molecules in a cell reach their toxic levels. This results in failure and defectiveness of almost every system in a human body including nervous system, circulation system, digestive system, and muscles. Expansion Therapeutics has been on the forefront in providing some medications to combat the illness.
The Chairman of the Board of Directors of Expansion Therapeutics, Scott Rocklage stated that they get their research from the laboratory of Dr. Disney who is the main researcher of the cure of this disorder in the team. Learn more: http://people.equilar.com/bio/scott-rocklage-cidara-therapeutics-/salary/913398#.WWaMA9PytTY